Caribou Biosciences is a clinical-stage biopharmaceutical company specializing in CRISPR genome editing to craft transformative therapies for patients with severe diseases. The organization utilizes advanced genome-editing technology to develop precise cell therapies, particularly focusing on off-the-shelf allogeneic treatments from their CAR-T and CAR-NK platforms, aimed at addressing hematologic malignancies and solid tumors. Caribou fosters a collaborative and inclusive culture, emphasizing the value of diverse perspectives and the importance of individual engagement within teams. The company’s mission is rooted in the belief that innovative cell therapies can significantly impact patient outcomes, driving efforts to make these therapies readily accessible. With operations based in Berkeley, California, and remote opportunities available, Caribou encourages a dynamic work environment that supports professional growth and development.